Navigation Links
Novel mechanism found that may boost impaired function of leukemia protein
Date:2/29/2008

NEW YORK, February 29, 2008 A new study led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) reports on a novel mechanism that can enhance the function of a protein that is frequently impaired in patients with acute forms of leukemia. The protein, called AML1, plays a critical role in the development of the blood system and in the production of platelets and immune cells. The findings are published in the March 1, 2008, issue of Genes & Development.

According to the study, investigators identified the methyltransferase enzyme that controls the activity of the normal AML1 protein also called RUNX1 demonstrating its ability to regulate the function of transcription factors, proteins that control cell fate by turning genes on or off. The researchers found that the cellular pathways that regulate the activity of the normal AML1 protein through a process called arginine methylation cannot similarly regulate the activity of AML1-ETO, a protein associated with causing acute leukemia.

Methylation is the process by which methyltransferases catalyze the attachment of a methyl group to DNA or protein in order to regulate gene expression or protein function. Demethylase enzymes that remove methyl groups from proteins have only recently been discovered.

By manipulating the activity of these enzymes, it may be possible to promote the activity of the normal protein, and thereby lessen the impact of the protein that promotes leukemia, said the studys senior author Stephen D. Nimer, MD, Chief of the Hematology Service at MSKCC. We are just beginning to explore whether we can tilt the balance toward a normally functioning AML1 protein in leukemic cells and either trigger their death or their reversion to normal behavior.

There are currently no available drugs that target protein methylation, although two drugs that target DNA methylation are FDA approved for treating patients with myelodysplastic syndromes.

We hope to utilize these new findings to help develop and ultimately test new treatment strategies for patients with either myeloid or lymphoid types of acute leukemia, said the studys first author, Xinyang Zhao, a member of Dr. Nimers laboratory.

Dr. Nimer has been researching the AML1-ETO protein at MSKCC since 1993. He and his colleagues first demonstrated in 1995 that AML1-ETO functions as a transcriptional repressor and dominantly inhibits AML1 function.


'/>"/>

Contact: Esther Napolitano
napolite@mskcc.org
212-639-3139
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Related medicine news :

1. Novel method to reveal drug targets
2. Novel link between excessive nutrient levels and insulin resistance
3. Novel organic metal hybrids that will revolutionize materials science and chemical engineering
4. Novel mathematical model predicts new wave of drug-resistant HIV infections in San Francisco
5. Novel approach strips staph of virulence
6. UCSD research team identifies novel anticancer drug from the sea
7. Novel compound may lessen heart attack damage
8. Novel molecules developed at UB can boost vaccine potency
9. Novel small molecule therapy shows benefit for anemic patients via hydration of red blood cells
10. Novel vaccine concept developed by scientists at the Wistar Institute
11. Tibotec Pharmaceuticals a Respectful Partner to HIV Community in Pricing of Novel New HIV NNRTI, INTELENCE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type of skin ... blame for the majority of skin cancer deaths. More than 10,000 people are expected to ... at diagnosis is 62, it is the one of the most commonly diagnosed cancers in ...
(Date:4/29/2016)... , ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon ... is a very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to ... is a procedure that involves one or both jaw bones. This surgery is performed to ...
(Date:4/29/2016)... ... April 29, 2016 , ... For those who skip ... meal to miss. That was among the many new lifestyle diet tips offered by ... Sharon Kleyne Hour® Power of Water® radio show. Bonny and Lawrence noted that because ...
(Date:4/29/2016)... ... 29, 2016 , ... Innovations with Ed Begley Jr., announced ... airing third quarter 2016 via Discovery Channel. Dates and show times TBA. , ... located in Greenwood, Wisconsin applies product research and development and continuous technological improvements ...
(Date:4/29/2016)... ... 2016 , ... CURE Media Group , the nation’s ... today announced that Lynne Malestic, RN, of Eisenhower Lucy Curci Cancer Center in ... Oncology Nursing , which honors nurses who have dedicated their careers to helping ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016 , Net Sales of ... basis over the prior year period, and an increase of ... , Diluted EPS for the first quarter were $0.52 reported, ... $2.00 adjusted, an increase of 29.9% over the prior year ... adjusted earnings guidance for 2016 Zimmer Biomet Holdings, ...
(Date:4/28/2016)... April 28, 2016 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug delivery ... upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... New York . Nadav Kidron , ... conference. Presentation Details:   PIONEERS ...
(Date:4/28/2016)... Calif. , April 28, 2016 /PRNewswire/ ... Validation Lifecycle Management Solutions (VLMS) today announced ... and services for sufferers of chronic kidney ... System to manage their corporate validation process. ... seeking a software solution to manage their ...
Breaking Medicine Technology: